Soho Flordis International · Australia · Swiss-Manufactured
Flordis
Australian evidence-based herbal medicine, manufactured in Switzerland, clinically researched extracts.
Shop now →The story
The two products distributed in South Africa illustrate the model. KeenMind contains CDRI 08, a Bacopa monnieri extract first researched at the Central Drug Research Institute in India in 1974, supported by six human clinical trials and over 40 years of cognitive research. Ellura contains a 36mg proanthocyanidin (PAC) cranberry extract from the same Australian-grown cranberry, dosed at the level used in the urinary tract health literature. The extracts are manufactured in Switzerland under Source-to-Patient quality controls, which is the brand's commercial differentiator: same extract, same potency, same trial-tested dose in every capsule.
An herbal medicine is only as good as the specific extract inside it. Generic Bacopa is not CDRI 08. Generic cranberry is not 36mg PAC. The extract is the medicine.The Flordis Team, SFI Health
What makes them different
-
01
Branded Extracts
Flordis products use specific, named, clinically researched extracts (CDRI 08 Bacopa, 36mg PAC cranberry), not generic plant powders. The trial data attaches to the extract, not the species, which is why the brand insists on naming the source.
-
02
Swiss Manufacturing
Extracts are produced in Switzerland under pharmaceutical-grade controls (GMP-equivalent). The Source-to-Patient programme tracks each batch from harvest through extraction to final capsule, with consistent potency batch-to-batch.
-
03
Clinical Trial Backing
KeenMind has six published human trials supporting cognitive and learning benefits. Ellura's 36mg PAC dose is the level used in urinary health research. Trial-based dosing is the foundation of the formulation.
-
04
Australian Heritage
Soho Flordis International is headquartered in Australia, with a research and regulatory tradition tied to Australia's TGA framework for complementary medicines. The brand operates in South Africa, Australia, the Middle East, and the Americas.
The shelf favourites
The handful we reach for most. Ranked by what actually sells, with the why for each.
-
Flordis - KeenMind 60 Capsules
R399.00
CDRI 08 Bacopa monnieri extract for memory, concentration, and learning retention. Standard dose is two capsules daily with breakfast. Used by students, knowledge workers, and adults concerned with cognitive ageing.
View product → -
Flordis Ellura Urinary Tract Health Capsules
R319.00
36mg PAC cranberry extract for urinary tract health and reducing the frequency of recurrent cystitis. One capsule per day. The PAC level matches the dose used in published cranberry research, which is higher than most cranberry juice or generic supplement options.
View product →
Shop the full Flordis range below.
All Flordis products ↓
Flordis Ellura Urinary Tract Health Capsules
Flordis - KeenMind 60 Capsules
Touring the range
Three doorways into the brand: entry, classic, specialty.
KeenMind for memory and focus
The cognitive pillar of the range. CDRI 08 Bacopa requires consistent daily use for 8 to 12 weeks to show its full effect, which mirrors the trial protocols. Not a same-day stimulant; a long-cycle cognitive support.
Ellura for recurrent UTI prevention
Daily prophylactic for women with recurrent urinary tract infections. The 36mg PAC dose blocks bacterial adhesion to the bladder wall. Used as a daily preventive, not as treatment for an active infection.
Match the extract to the need
The two products solve different problems. KeenMind is for cognitive function; Ellura is for urinary health. There is no overlap. If you are unsure which fits, the indication is on the label and the trial data is the differentiator from generic alternatives.
What the brand stands behind
-
Swiss-Manufactured
All extracts are produced in Switzerland under GMP-equivalent quality controls. Batch-to-batch potency consistency is part of the contract.
-
Clinically Researched
CDRI 08 has six published human trials. The 36mg PAC level in Ellura matches the dose used in urinary tract health research literature.
-
Source-to-Patient
SFI Health's internal quality programme tracks each batch from raw plant through extraction, formulation, and final packaging. Traceability is documented end-to-end.
-
TGA-Listed Heritage
The Australian parent company operates under Australia's Therapeutic Goods Administration framework for complementary medicines, which is one of the stricter global regimes.
-
40+ Years Research
The CDRI 08 extract was first researched in 1974 at India's Central Drug Research Institute and has been studied continuously since then.
About this brand
Common questions customers ask about the brand and its products.